BACKGROUND AND PURPOSE: Tumor hypoxia and tumor cell repopulation are known factors determining radiation response. Accelerated radiotherapy as a method to counteract cellular repopulation was combined with carbogen (95% O2 + 5% CO2) breathing and oral administration of nicotinamide as a means to improve tumor perfusion and oxygenation. The feasibility, toxicity and clinical effectiveness of this approach as a voice-preserving treatment for carcinoma of the larynx was assessed in a prospective study. PATIENTS AND METHODS: Sixty-two patients with stage III-IV laryngeal carcinoma were treated with a schedule of accelerated radiotherapy. The total radiation dose to the primary tumor was 64 Gy and that to the metastatic nodes was 68 Gy delivered in fractions of 2 Gy over 35-37 days. Radiotherapy was combined with carbogen breathing in the initial 11 patients and with both carbogen and nicotinamide administration in the subsequent 51 patients. RESULTS: After a median follow-up of 24 months, the actuarial local control rate at 2 years was 92%. This is higher than any previous report in the literature for this category of patients. Five patients had a local tumor recurrence and underwent laryngectomy. There was one regional recurrence. Including salvage surgery the loco-regional control rate was 100%. Four patients developed distant metastases and died. The actuarial overall survival rate at 2 years was 85%. Toxicity was increased relative to conventional radiotherapy but was considered as acceptable. One patient underwent laryngectomy for radiation-induced cartilage necrosis. CONCLUSION: These preliminary results indicate that advanced laryngeal cancer can be controlled in a high proportion of patients when treated with accelerated radiotherapy combined with carbogen and nicotinamide. This approach offers excellent possibilities for larynx preservation.
BACKGROUND AND PURPOSE:Tumorhypoxia and tumor cell repopulation are known factors determining radiation response. Accelerated radiotherapy as a method to counteract cellular repopulation was combined with carbogen (95% O2 + 5% CO2) breathing and oral administration of nicotinamide as a means to improve tumor perfusion and oxygenation. The feasibility, toxicity and clinical effectiveness of this approach as a voice-preserving treatment for carcinoma of the larynx was assessed in a prospective study. PATIENTS AND METHODS: Sixty-two patients with stage III-IV laryngeal carcinoma were treated with a schedule of accelerated radiotherapy. The total radiation dose to the primary tumor was 64 Gy and that to the metastatic nodes was 68 Gy delivered in fractions of 2 Gy over 35-37 days. Radiotherapy was combined with carbogen breathing in the initial 11 patients and with both carbogen and nicotinamide administration in the subsequent 51 patients. RESULTS: After a median follow-up of 24 months, the actuarial local control rate at 2 years was 92%. This is higher than any previous report in the literature for this category of patients. Five patients had a local tumor recurrence and underwent laryngectomy. There was one regional recurrence. Including salvage surgery the loco-regional control rate was 100%. Four patients developed distant metastases and died. The actuarial overall survival rate at 2 years was 85%. Toxicity was increased relative to conventional radiotherapy but was considered as acceptable. One patient underwent laryngectomy for radiation-induced cartilage necrosis. CONCLUSION: These preliminary results indicate that advanced laryngeal cancer can be controlled in a high proportion of patients when treated with accelerated radiotherapy combined with carbogen and nicotinamide. This approach offers excellent possibilities for larynx preservation.
Authors: R J Gillies; Z M Bhujwalla; J Evelhoch; M Garwood; M Neeman; S P Robinson; C H Sotak; B Van Der Sanden Journal: Neoplasia Date: 2000 Jan-Apr Impact factor: 5.715
Authors: Narges K Tafreshi; Mark C Lloyd; Joshua B Proemsey; Marilyn M Bui; Jongphil Kim; Robert J Gillies; David L Morse Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Ludwig J Dubois; Natasja G Lieuwes; Marco H M Janssen; Wenny J M Peeters; Albert D Windhorst; Joseph C Walsh; Hartmuth C Kolb; Michel C Ollers; Johan Bussink; Guus A M S van Dongen; Albert van der Kogel; Philippe Lambin Journal: Proc Natl Acad Sci U S A Date: 2011-08-23 Impact factor: 11.205
Authors: Janneke Schuuring; Mark Rijpkema; Hans Bernsen; Pieter Bernsen; Richard van der Maazen; Johannes Kaanders; Albert van der Kogel; Arend Heerschap Journal: J Neurooncol Date: 2002-04 Impact factor: 4.130
Authors: Leonard Che Fru; Steven L Jacques; Kwang P Nickel; Tomy Varghese; Michael W Kissick; Larry A DeWerd; Randall J Kimple Journal: Biomed Phys Eng Express Date: 2020-01-31